Tert promoter mutation as a potential predictive biomarker in bcg-treated bladder cancer patients

Wednesday, February 5th, 2020

Tert promoter mutation as a potential predictive biomarker in bcg-treated bladder cancer patients

Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found at:

https://www.mdpi.com/1422-0067/21/3/947/htm